Treatment of depression in an adolescent with cardiomyopathy and arrhythmia

Cardiol Young. 2015 Oct;25(7):1418-20. doi: 10.1017/S1047951114002303. Epub 2014 Nov 17.

Abstract

Patients with cardiomyopathy have a higher incidence of mood and anxiety disorders, resulting in greater probability for hospitalisation and increased risk for arrhythmia and death. We report a case of a 16-year-old boy with Danon disease, Wolff-Parkinson-White syndrome, and hypertrophic cardiomyopathy, who later developed depression and significant weight loss. The patient was successfully treated for his anxiety and depression with mirtazapine without any adverse cardiac effects.

Keywords: Arrhythmia; Danon disease; depression; hypertrophic cardiomyopathy; mirtazapine.

MeSH terms

  • Adolescent
  • Antidepressive Agents, Tricyclic / therapeutic use*
  • Anxiety / drug therapy*
  • Cardiomyopathy, Hypertrophic / psychology*
  • Depression / drug therapy*
  • Electrocardiography
  • Glycogen Storage Disease Type IIb / psychology*
  • Humans
  • Male
  • Mianserin / analogs & derivatives*
  • Mianserin / therapeutic use
  • Mirtazapine
  • Weight Loss / drug effects
  • Wolff-Parkinson-White Syndrome / diagnosis*

Substances

  • Antidepressive Agents, Tricyclic
  • Mianserin
  • Mirtazapine